S., Zakher, B., Daeges, M., Pappas, M., & Chou, R
Several studies have estimated the costeffectiveness of GLP1s for obesity from a healthcare perspective, considering costs for screening and treatment against savings from improved weight and health outcomes and corresponding longterm reductions in healthcare utilization, including downstream accumulated health benefits
The students I saw exhibited a startup mentality - seeing potential and thinking about how to solve problems through technology innovation, a smart business model and visible commitment
Science 359:11511156
Ojosnegros S, Seriola A, Godeau AL, Veiga A (2021) Embryo implantation in the laboratory: an update on current techniques
Retatrutide is an investigational triple agonist acting on GLP-1, GIP, and glucagon receptors, but it has not received MHRA marketing authorisation and cannot be legally prescribed in the UK